News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biotech Firm Glycart Biotechnology AG Caps $13.6M Series A Round


10/19/2005 5:09:18 PM

Glycart Biotechnology, a biotechnology company focused on the development and commercialization of antibodies for the treatment of cancer and autoimmune diseases, said it has closed its Series A round of financing, raising CHF 18 million ($13.6 million.)


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES